drugset / Trial / NCT02997176

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

NCT02997176

Phase 1 Completed 38 enrolled Pfizer Medivation, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.

Timeline

Start
2016-09-30
Primary completion
2020-02-12
Completion
2020-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Talazoparib Small molecule 0.5 mg Oral

Indications